Mirae Asset Sharekhan's research report on Cipla
Cipla has robust domestic and global product pipelines. US product pipeline to be healthy and will be key to driving growth from H2FY26E and contribute significantly from FY27E onwards. Strong presence in key therapies, large trade generics portfolio and a growing consumer health portfolio provide visibility for FY27 and beyond domestically.
Outlook
With the current valuation overhang on the sector, the stock trades at close to its four-year average 1 year forward P/E of 24x and with the triggers eyed from H2FY26, we maintain a Buy, valuing the stock at 26x on FY27E EPS of Rs. 67.5 and arrive at a price target of Rs. 1,754.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
